In this context, it is noteworthy that systemic levels of IL-6 are increased in various types of severe lung cancer and are not only predictive of disease progression [146] but also of an unsatisfactory response to PD-1-targeted immunotherapy in NSCLC [147]. This evidence concerns the gene PDCD1 and lung cancer.